Department of Oral and Maxillofacial-Head Neck Oncology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Zhizaoju Road 639, 200011, Shanghai, China.
Mol Biol Rep. 2022 Jun;49(6):4829-4840. doi: 10.1007/s11033-022-07336-x. Epub 2022 Jun 16.
Tumor-derived exosomes, as emerging regulators of intercellular communication, are important for tumorigenesis and development in multiple tumors. The purpose of this study was to investigate whether exosomal miR-626 exists. More importantly, if exosomal miR-626 exists, the mechanism by which it is transferred into neighboring cancer cells and contributes to tumor progression needs to be clarified.
The expression of miRNA and mRNA are analyzed by RT-qPCR. Proliferation, colony formation, wound healing, cell cycle are carried out to assess the function of exosomal miR-626. Furthermore, a xenograft experiment is utilized to conform the cancer-promoting role of exosomal miR-626 in oral cancer. Here, we showed that miR-626 is upregulated in oral cancer-derived exosomes and can be transferred between oral cancer cells. Exosomal miR-626 promotes cancer cell proliferation, colony formation, migration and G0/G1-to-S phase transition. Nuclear factor I/B (NFIB), a tumor suppressor gene in various cancers, was predicted to be a potential target of miR-626 by using three algorithms. Luciferase reporter assay data revealed that miR-626 can directly bind to the 3'-UTR of NFIB and subsequently suppress its expression and downstream signaling. Restoration of NFIB expression rescued the malignant phenotype induced by exosomal miR-626. In addition, exosomal miR-626 administration facilitated cancer growth in a xenograft tumor model, accompanied by downregulation of NFIB expression.
Our data demonstrate that exosomal miR-626 can facilitate the development of oral cancer by inhibiting the expression of its target NFIB. Exosomal miR-626 might be a therapeutic target for oral cancer.
肿瘤来源的外泌体作为细胞间通讯的新兴调节因子,在多种肿瘤的发生和发展中具有重要作用。本研究旨在探讨外泌体 miR-626 是否存在。更重要的是,如果外泌体 miR-626 存在,需要阐明其进入邻近癌细胞并促进肿瘤进展的机制。
通过 RT-qPCR 分析 miRNA 和 mRNA 的表达。进行增殖、集落形成、划痕愈合、细胞周期实验以评估外泌体 miR-626 的功能。此外,利用异种移植实验证实外泌体 miR-626 在口腔癌中的促癌作用。在这里,我们表明 miR-626 在口腔癌衍生的外泌体中上调,并可在口腔癌细胞之间转移。外泌体 miR-626 促进癌细胞增殖、集落形成、迁移和 G0/G1 至 S 期转变。核因子 I/B(NFIB)是多种癌症中的肿瘤抑制基因,通过三种算法预测为 miR-626 的潜在靶标。荧光素酶报告基因检测数据显示,miR-626 可以直接结合 NFIB 的 3'-UTR,随后抑制其表达和下游信号。NFIB 表达的恢复挽救了外泌体 miR-626 诱导的恶性表型。此外,外泌体 miR-626 的给药促进了异种移植肿瘤模型中的癌症生长,同时伴随着 NFIB 表达的下调。
我们的数据表明,外泌体 miR-626 通过抑制其靶基因 NFIB 的表达促进口腔癌的发展。外泌体 miR-626 可能是口腔癌的治疗靶点。